Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who ...

Annual Meeting held in Chicago, IL, was host to a State of the Science session on novel diagnostics and therapeutics in renal cell and urothelial carcinomas. Dr. Wulff-Burchfield discussed strategies ...

Urothelial carcinoma is cancer of the urinary system. The urothelium is a kind of epithelial (protective) lining of the urinary system, which includes the urinary tract, bladder, your ureters (the ...

Chinese-herb nephropathy is a progressive form of renal fibrosis that develops in some patients who take weight-reducing pills containing Chinese herbs. Because of a manufacturing error, one of ...

Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive ...

The FDA has granted clearance to the IND applications for both the therapeutic ( [ 225 Ac]Ac-AKY-1189) and imaging ( [ 64 ...

Preferred first-line (1L) treatment for metastatic urothelial carcinoma (mUC) after prior immune checkpoint inhibitor (ICI) therapy: Results from a national survey. This is an ASCO Meeting Abstract ...

The firm will study AKY-1189 in Nectin-4-expressing tumors, including urothelial and triple-negative breast cancer.

which demonstrated survival improvements for patients treated with enfortumab vedotin and pembrolizumab that were previously unprecedented in locally advanced or metastatic urothelial cancer.

What Is Transitional Cell Carcinoma of the Prostate? Transitional, or urothelial, cells make up the lining inside parts of the urinary tract. They’re in the bladder, urethra, and ureters.

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers ...

Enfortumab vedotin-ejfv and pembrolizumab show superior PFS and OS compared to chemotherapy in urothelial carcinoma. The combination therapy's benefits are consistent across subgroups, including ...